MCID: NDL021
MIFTS: 50

Nodular Lymphocyte Predominant Hodgkin Lymphoma

Categories: Cancer diseases, Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards integrated aliases for Nodular Lymphocyte Predominant Hodgkin Lymphoma:

Name: Nodular Lymphocyte Predominant Hodgkin Lymphoma 59 73
Nlphl 59

Characteristics:

Orphanet epidemiological data:

59
nodular lymphocyte predominant hodgkin lymphoma
Prevalence: 1-9/1000000 (Worldwide),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards based summary : Nodular Lymphocyte Predominant Hodgkin Lymphoma, also known as nlphl, is related to lymphoma, hodgkin, classic and lymphoma. An important gene associated with Nodular Lymphocyte Predominant Hodgkin Lymphoma is BCL6 (B Cell CLL/Lymphoma 6), and among its related pathways/superpathways are NF-kappaB Signaling and Transcriptional misregulation in cancer. The drugs Vinblastine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are hyperhidrosis and splenomegaly

Wikipedia : 76 Nodular lymphocyte predominant Hodgkin\'s lymphoma (NLPHL) is an indolent CD20(+) form of... more...

Related Diseases for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 32.7 BCL6 PAX5 PTPRC
2 lymphoma 30.8 BCL6 CCND1 PAX5
3 b-cell lymphomas 30.2 BCL6 CCND1 PAX5
4 lymphoma, non-hodgkin, familial 28.4 BCL6 CCND1 PAX5 PTPRC
5 t-cell/histiocyte rich large b cell lymphoma 11.7
6 hodgkin's granuloma 10.6
7 diffuse large b-cell lymphoma 10.3
8 heart lymphoma 10.3 BCL6 PTPRC
9 testicular lymphoma 10.3 BCL6 PTPRC
10 composite lymphoma 10.3 BCL6 PAX5
11 intraocular lymphoma 10.3 BCL6 PAX5
12 colon lymphoma 10.3 BCL6 PTPRC
13 primary central nervous system lymphoma 10.3 BCL6 PAX5
14 epidural neoplasm 10.2 BCL6 PTPRC
15 lymphosarcoma 10.2 BCL6 PTPRC
16 plasmablastic lymphoma 10.2 BCL6 PTPRC
17 multicentric castleman disease 10.2 BCL6 PAX5
18 lymphatic system cancer 10.2 BCL6 PTPRC
19 mediastinal malignant lymphoma 10.2 BCL6 PAX5
20 hodgkin's lymphoma, lymphocytic depletion 10.2 PAX5 PTPRC
21 lung lymphoma 10.2 BCL6 PAX5
22 splenic marginal zone lymphoma 10.1 BCL6 PAX5
23 mature b-cell neoplasm 10.1 BCL6 PTPRC
24 peripheral t-cell lymphoma 10.1
25 progressive transformation of germinal centers 10.1
26 lymphoblastic lymphoma 10.1 BCL6 PTPRC
27 myeloid sarcoma 10.1 PAX5 PTPRC
28 cll/sll 10.0 CCND1 PAX5
29 hemolytic anemia 10.0
30 hepatitis 10.0
31 sarcoma 10.0
32 leiomyoma 10.0
33 cervicitis 10.0
34 kaposi sarcoma 10.0
35 polyradiculopathy 10.0
36 li-fraumeni syndrome 10.0
37 adult lymphoma 10.0
38 anemia, autoimmune hemolytic 10.0
39 thyroiditis 10.0
40 mediastinitis 10.0
41 li-fraumeni syndrome 2 10.0
42 acute liver failure 10.0
43 warthin tumor 10.0
44 primary mediastinal large b-cell lymphoma 10.0
45 lymphoma, mucosa-associated lymphoid type 9.8 BCL6 CCND1
46 anaplastic large cell lymphoma 9.8 PAX5 PTPRC
47 reticulosarcoma 9.7 BCL6 PAX5 PTPRC
48 respiratory system cancer 9.7 CCND1 PDCD1
49 mantle cell lymphoma 9.6 BCL6 CCND1 PAX5
50 mutagen sensitivity 9.6 CCND1 IGF1

Graphical network of the top 20 diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:



Diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma

Symptoms & Phenotypes for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Human phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

59 32 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000975
2 splenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001744
3 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
4 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
5 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
6 immunodeficiency 59 32 hallmark (90%) Very frequent (99-80%) HP:0002721
7 pruritus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000989
8 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
9 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
10 breast carcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0003002
11 lymphadenopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0002716
12 abnormality of bone marrow cell morphology 59 32 occasional (7.5%) Occasional (29-5%) HP:0005561
13 b-cell lymphoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0012191
14 lymphoma 59 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.13 CCND1 PDCD1 PTPRC
2 Reduced mammosphere formation GR00396-S 8.92 BCL6 CCND1 IGF1 PTPRC

MGI Mouse Phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.97 BCL6 CCND1 IGF1 PAX5 PDCD1 PTPRC
2 growth/size/body region MP:0005378 9.93 CCND1 IGF1 PAX5 PDCD1 PTPRC BCL6
3 hematopoietic system MP:0005397 9.91 BCL6 CCND1 IGF1 PAX5 PDCD1 PTPRC
4 endocrine/exocrine gland MP:0005379 9.88 BCL6 CCND1 IGF1 PDCD1 PTPRC
5 immune system MP:0005387 9.88 BCL6 CCND1 IGF1 PAX5 PDCD1 PTPRC
6 mortality/aging MP:0010768 9.85 BCL6 CCND1 IGF1 PAX5 PDCD1 PTPRC
7 neoplasm MP:0002006 9.72 CCND1 IGF1 PAX5 PDCD1 PTPRC
8 nervous system MP:0003631 9.65 IGF1 PAX5 PDCD1 PTPRC CCND1
9 normal MP:0002873 9.55 BCL6 CCND1 IGF1 PAX5 PTPRC
10 respiratory system MP:0005388 9.35 BCL6 CCND1 IGF1 PDCD1 PTPRC
11 skeleton MP:0005390 9.02 CCND1 IGF1 PAX5 PDCD1 PTPRC

Drugs & Therapeutics for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Drugs for Nodular Lymphocyte Predominant Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinblastine Approved Phase 4,Phase 2 865-21-4 13342 241903
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3 50-18-0, 6055-19-2 2907
3
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
6 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
7 glucocorticoids Phase 4,Phase 3
8 Gastrointestinal Agents Phase 4,Phase 3
9 Hormone Antagonists Phase 4,Phase 3
10 Hormones Phase 4,Phase 3
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
12 Peripheral Nervous System Agents Phase 4,Phase 3
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antiemetics Phase 4,Phase 3
15 Anti-Inflammatory Agents Phase 4,Phase 3
16 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Autonomic Agents Phase 4,Phase 3
18 Antimitotic Agents Phase 4,Phase 3,Phase 2
19 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Hormonal Phase 4,Phase 3
21 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2
22 Prednisolone acetate Phase 4
23 Methylprednisolone acetate Phase 4
24 Methylprednisolone Hemisuccinate Phase 4
25 Neuroprotective Agents Phase 4
26 Prednisolone hemisuccinate Phase 4
27 Prednisolone phosphate Phase 4
28 Protective Agents Phase 4
29
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
30
Etoposide Approved Phase 3 33419-42-0 36462
31
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
32
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
33
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
34
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
35
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
36
Cortisone acetate Approved, Investigational Phase 3 1950-04-4, 50-04-4 5745
37
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
38
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
39
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
40
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
41
Doxil Approved June 1999 Phase 3 31703
42 Podophyllotoxin Phase 3 518-28-5
43
Cortisone Phase 3 53-06-5 222786
44 Dexamethasone acetate Phase 3 1177-87-3
45
Isophosphamide mustard Phase 3,Phase 2 0
46
protease inhibitors Phase 3
47 Adjuvants, Immunologic Phase 3,Phase 2
48 HIV Protease Inhibitors Phase 3
49 Topoisomerase Inhibitors Phase 3
50 Dermatologic Agents Phase 3

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
2 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
3 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
4 Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Completed NCT01187303 Phase 2 Ofatumumab
5 Rituximab in Treating Patients With Hodgkin's Lymphoma Completed NCT00003820 Phase 2 Rituximab
6 Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy Completed NCT00381940 Phase 2 ifosfamide;bortezomib;vinorelbine tartrate
7 A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed NCT01460940 Phase 2 panobinostat;lenalidomide
8 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma Completed NCT00132028 Phase 2 vorinostat
9 Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. Completed NCT01022996 Phase 2 Everolimus (RAD001)
10 Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) Recruiting NCT02626884 Phase 2 Ibrutinib
11 Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Active, not recruiting NCT01535924 Phase 1, Phase 2 gemcitabine hydrochloride;bendamustine hydrochloride
12 Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Terminated NCT00288067 Phase 1, Phase 2 fenretinide;rituximab
13 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
14 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Active, not recruiting NCT01588015 Phase 1
15 Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma Completed NCT01366157

Search NIH Clinical Center for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Genetic Tests for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Anatomical Context for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards organs/tissues related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

41
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Lung, Monocytes

Publications for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Articles related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

(show top 50) (show all 157)
# Title Authors Year
1
Coping With Knife: Postoperative Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29413265 )
2018
2
Long-term follow-up of 2 patients treated with <sup>90</sup> Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma. ( 29719928 )
2018
3
Unfavorable presentation but comparable outcome: Presentation and outcome of children with nodular lymphocyte predominant Hodgkin lymphoma from India. ( 29893471 )
2018
4
Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29401099 )
2018
5
R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma. ( 29537344 )
2018
6
Erratum: Lydia Visser et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma, Int. J. Mol. Sci. 2016, 17, 2127. ( 29351228 )
2018
7
Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival. ( 29479868 )
2018
8
Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29309302 )
2018
9
High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. ( 28971503 )
2018
10
Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data. ( 28737250 )
2017
11
GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities. ( 28877074 )
2017
12
Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. ( 27998726 )
2017
13
Variant histology nodular lymphocyte predominant Hodgkin lymphoma - a route to transformation? ( 28369705 )
2017
14
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. ( 29222274 )
2017
15
Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group. ( 28802087 )
2017
16
T-cell rosettes in nodular lymphocyte-predominant Hodgkin lymphoma. ( 28183747 )
2017
17
Nodular Lymphocyte-Predominant Hodgkin Lymphoma in Progressive Transformation of Germinal Centers. ( 29348956 )
2017
18
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE &amp;amp; CCLG groups. ( 28220934 )
2017
19
Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Real-world Case Series of Consecutive Patients Treated by a Single Multidisciplinary Team in the East of England From 1999 to 2015. ( 28935378 )
2017
20
Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation. ( 28902083 )
2017
21
J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. ( 28851661 )
2017
22
Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry. ( 28233899 )
2017
23
Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma. ( 28737231 )
2017
24
Cyclin D1 expression and polysomy in lymphocyte-predominant cells of nodular lymphocyte-predominant Hodgkin lymphoma. ( 28038705 )
2017
25
Nodular Lymphocyte Predominant Hodgkin Lymphoma of the Ileum. ( 29230339 )
2017
26
Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 28522441 )
2017
27
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. ( 26837698 )
2016
28
A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma. ( 27708232 )
2016
29
Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 27999289 )
2016
30
Atypical variants of nodular lymphocyte predominant Hodgkin lymphoma show low microvessel density and vessels of distention type. ( 27816718 )
2016
31
Nodular Lymphocyte Predominant Hodgkin Lymphoma Presenting with Unilateral Orbital Involvement. ( 27015240 )
2016
32
Nodular lymphocyte-predominant Hodgkin lymphoma. ( 27496311 )
2016
33
An unusual clinical and pathological presentation of a nodular lymphocyte predominant Hodgkin lymphoma (&amp;quot;Poppema Lennert&amp;quot; lymphoma). ( 27532537 )
2016
34
Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group. ( 26996288 )
2016
35
A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. ( 26732883 )
2016
36
Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. ( 26762971 )
2016
37
A case of composite classical and nodular lymphocyte predominant Hodgkin lymphoma with progression to diffuse large B-cell non-Hodgkin lymphoma: Diagnostic difficulty in fine-needle aspiration cytology. ( 27888658 )
2016
38
Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. ( 26658840 )
2016
39
Nodular Lymphocyte Predominant Hodgkin Lymphoma of the Thyroid. ( 28044111 )
2016
40
The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children. ( 26872637 )
2016
41
Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma. ( 26913966 )
2016
42
Diagnostic Utility of Flow Cytometry Analysis of Reactive T Cells in Nodular Lymphocyte-Predominant Hodgkin Lymphoma. ( 26712878 )
2016
43
Management of nodular lymphocyte predominant hodgkin lymphoma in the modern era. ( 25863755 )
2015
44
Characteristics and outcomes of patients with nodular lymphocyte-predominant hodgkin lymphoma versus those with classical hodgkin lymphoma: a population-based analysis. ( 25863756 )
2015
45
Lymphocyte-Rich Classical Hodgkin Lymphoma. A Case with Difficulty in Distinguishing from Nodular Lymphocyte-Predominant Hodgkin Lymphoma. ( 26106003 )
2015
46
Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma. ( 26149195 )
2015
47
Nodular Lymphocyte-Predominant Hodgkin Lymphoma in a Warthin Tumor of the Parotid Gland: A Case Report and Literature Review. ( 26169920 )
2015
48
Nodular lymphocyte predominant Hodgkin lymphoma: Clincopathological study of 25 cases from Japan with a reappraisal of tissue associated macrophages. ( 26538151 )
2015
49
Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. ( 26685097 )
2015
50
High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma. ( 26467917 )
2015

Variations for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Expression for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Search GEO for disease gene expression data for Nodular Lymphocyte Predominant Hodgkin Lymphoma.

Pathways for Nodular Lymphocyte Predominant Hodgkin Lymphoma

GO Terms for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Biological processes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.33 BCL6 IGF1 PDCD1
2 response to organic substance GO:0010033 9.26 CCND1 IGF1
3 humoral immune response GO:0006959 8.96 PAX5 PDCD1
4 positive regulation of B cell proliferation GO:0030890 8.62 BCL6 PTPRC

Sources for Nodular Lymphocyte Predominant Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....